v3.26.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Operating Activities:      
Net loss   $ (84,937) $ (25,545)
Change in fair value of warrant liability [note 5] $ 48,528 48,528  
Change in fair value of pre-funded warrant liability [note 5] 144 144  
Warrant issuance cost 8,799 8,799  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization [note 3]   115 117
Stock-based compensation [note 7[c], note 7[e] and note 7[f]] 6,955 6,270 5,120
Amortization of 2024 SVB convertible term loan transaction costs [note 6]   23 28
Change in fair value of contingent consideration [note 4 and note 5] 100 (185) 188
Accretion of discount on marketable securities   (686)  
Amortization of premium on securities   12  
Changes in operating assets and liabilities:      
Accrued compensation   1,017 (1,464)
Net cash used in operating activities   (17,709) (20,157)
Financing Activities:      
Proceeds from exercise of warrants   21  
Proceeds from employee share purchase plan   160  
Proceeds from option exercise   55  
Net cash provided by financing activities   168,479 41,222
Investing Activities:      
Purchase of property and equipment   (16)  
Purchase of intangible assets   (170)  
Purchase of marketable securities   (139,974) (4,260)
Maturities of marketable securities   16,632 22,316
Net cash provided by (used in) investing activities   (123,528) 18,056
Effect of exchange rate changes on cash   2  
Net increase (decrease) in cash, cash equivalents and restricted cash   27,244 39,121
Cash, cash equivalents and restricted cash at beginning of the period   20,949 12,773
Cash, cash equivalents and restricted cash at end of the period $ 48,193 48,193 51,894
June 2025 Public Offering [Member]      
Financing Activities:      
Proceeds from public offering, net of issuance costs     41,222
April 2026 Private Placement [Member]      
Financing Activities:      
Proceeds from public offering, net of issuance costs   168,243  
Nonrelated Party [Member]      
Changes in operating assets and liabilities:      
Prepaid expenses and other assets   2,547 592
Accounts payable   (253) (732)
Accrued liabilities, other   483 646
Accrued clinical liabilities   219 $ 893
Related Parties [Member]      
Changes in operating assets and liabilities:      
Prepaid expenses and other assets   7  
Accounts payable   (8)  
Accrued liabilities, other   15  
Accrued clinical liabilities   $ 181